Ensysce Biosciences (ENSC) Stock Overview
A clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ENSC Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Ensysce Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.77 |
| 52 Week High | US$10.96 |
| 52 Week Low | US$1.53 |
| Beta | 1.15 |
| 1 Month Change | -17.29% |
| 3 Month Change | -15.71% |
| 1 Year Change | -76.46% |
| 3 Year Change | -99.66% |
| 5 Year Change | -100.00% |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| ENSC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.3% | 4.4% | 2.9% |
| 1Y | -76.5% | 17.5% | 12.5% |
Return vs Industry: ENSC underperformed the US Biotechs industry which returned 17.4% over the past year.
Return vs Market: ENSC underperformed the US Market which returned 11.4% over the past year.
Price Volatility
| ENSC volatility | |
|---|---|
| ENSC Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ENSC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENSC's weekly volatility has decreased from 19% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 8 | D. Kirkpatrick | www.ensysce.com |
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection.
Ensysce Biosciences, Inc. Fundamentals Summary
| ENSC fundamental statistics | |
|---|---|
| Market cap | US$6.02m |
| Earnings (TTM) | -US$10.97m |
| Revenue (TTM) | US$4.49m |
Is ENSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENSC income statement (TTM) | |
|---|---|
| Revenue | US$4.49m |
| Cost of Revenue | US$10.57m |
| Gross Profit | -US$6.08m |
| Other Expenses | US$4.89m |
| Earnings | -US$10.97m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.10 |
| Gross Margin | -135.44% |
| Net Profit Margin | -244.49% |
| Debt/Equity Ratio | 44.3% |
How did ENSC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 18:34 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ensysce Biosciences, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Bradley Sorensen | Zacks Small-Cap Research |